Results: Embedded pragmatic clinical trials (PCTs) are set in routine health care, have broad eligibility criteria, and use routinely collected electronic data. Many consider them a breakthrough innovation in clinical research and a necessary step in clinical trial development. To identify barriers and success factors, we reviewed published embedded PCTs and interviewed 30 researchers and clinical leaders in 7 US delivery systems.
| INTRODUCTION
In a learning health system, evidence is both generated and applied as a natural product of the care process. 1 An essential element of a learning health system is to collect and analyze data to generate knowledge. 2 Many study designs exist to achieve this. While there is no single best approach, the randomized controlled trial (RCT) is the gold standard in knowledge generation. 3 While traditional RCTs have strong internal validity, they are expensive and often have limited generalizability. 4 Observational studies, while less expensive and often applicable to broad populations, are prone to selection bias and confounding. Because of this, pragmatic randomized clinical trials embedded in routine health care (embedded pragmatic clinical trials [PCTs] ) may be an important part of a learning health system: They are less costly and can have better generalizability than traditional RCTs while having stronger internal validity than observational studies. 5, 6 The recent digitalization of health care data represents a potential quantum leap in the possibilities to conduct pragmatic research embedded in the routine delivery of health care. 1 Some embedded PCTs have indicated that very large costsavings might be possible compared to regular RCTs. The TASTE trial, a registry-based trial of thrombectomy added to stent placement for acute coronary occlusion, achieved >90% cost-saving
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Furthermore, "snowballing" was used in which reference lists of review and methodological papers were searched. Finally, researchers active in the field were asked for additional references. The searches were restricted to RCTs. Protocols and articles describing a trial design without reporting a result were excluded, as were reviews.
The studies had to have an active comparator that was a clinically relevant alternative for the patient population and broad eligibility criteria (as determined by reviewer). Data for primary end points needed to be collected in electronic, routinely used sources such as electronic health records (EHR), disease registries, other registries, or a combination of these sources, ie, no large infrastructure for data collection intended principally to support the trial's needs was allowed. Hybrid designs are sometimes used where some data such as patient reported outcomes (PROs) are collected for the trial. These were included if the primary end point was collected from existing data sources. We also included trials that used conventional followup for individuals who ceased to receive care at the institution whose electronic data provided the primary outcome. A flow diagram depicting the selection process is provided in Data S1. were used to test for statistical significance of differences in medians between groups.
One reviewer read each full text article and extracted information.
Subsequently, an independent reviewer performed a quality control and re-examined all the extracted data.
| Interviews
In Table S1 summarizes the data extracted from articles.
| Settings
About half (55%) of the studies occurred in only primary care settings.
Of the other studies, 16% were set in both primary care and hospitals and 14% in hospitals (but trials were also set in the community, schools, and, in one case, a prison. There were qualifying studies in 15 countries. The United States accounted for 55% of studies; the UK (14%) and Canada (7%) have contributed the next largest numbers.
Within the United States, over 30% of studies were performed at Veterans Administration facilities, Kaiser Permanente, and a few other integrated health care systems.
| Disease areas
Infectious diseases accounted for a quarter of the studies. Cardiovascular diseases were second with 18%, followed by diabetes (12%), cancer (9%), and behavioral health (5%).
| Types of interaction
As can be seen in Table 1 , more than 30 studies investigated different ways of using prompts and reminders directed at patients and clinicians to, predominantly, increase vaccination or screening rates.
Another frequent topic was feedback and other ways to increase adherence to clinical guidelines. Nine trials compared effectiveness between treatments.
Eighty-one percent of the studies had unspecified usual care as the comparator or allowed a variety of usual care practices. The rest had a specific usual care comparator.
| Trial design
These trials had a median of 5540 patients. Some studies involved millions of patients treated in the randomized health care units. Most (81 of 108) were cluster randomized, and 9 of these used a stepped wedge design. Fifty percent of studies used registries or administrative databases, 38% used EHRs and 12% a combination. Registry-based trials had a median of 4173 patients and EHR-based a median of 7740 patients.
Forty-three percent of studies collected data specifically for the study. PROs were collected in 11% of the studies. Cost data were collected in 25% of the trials. Individual informed consent was waived in all but 17% of the cluster randomized trials.
| Trial costs
Cost data were available for 64 trials. The mean and median cost per patient randomized was $478 and $97, respectively, in 2015 dollars.
Twenty-five percent of studies cost less than $19 per patient; 10 of the trials had a cost per patient above $1000.
As noted in Table 2 , US studies had a significantly higher median cost per patient than non-US studies, $187 vs $27 (P = .0088). Furthermore, registry-based trials were less expensive than EHR-based trials, and trials in pediatric populations had a lower median (but not mean) cost per patient than those in adults. Neither difference was statistically significant. The cost per patient for median cluster randomized trials was less expensive than the median for trials with individual randomization: $76 vs $204, although not statistically significant.
Behavioral health studies were the most expensive (median $931 vs $90).
Hybrid designs, where some data were collected principally for the trials' needs, made the median trial more than twice as expensive.
| Research funding
The NIH and AHRQ funded 16 trials each, the Veterans Health Administration 7, and CDC 8 trials. In total, they funded 74% of all US trials.
These trials also had more funding than other trials with a median Note: Individuals for whom a health system is responsible or residents of a geographic region. 
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| Results interviews
Results from interviews are presented as a conceptual model of barriers and success factors for embedded PCTs. See Figure 1 . The model is structured around 3 steps for embedded PCTs to influence practice:
(1) the decision of what to study, (2) obtaining, analyzing, and interpreting data, and (3) disseminating and implementing findings.
There are success factors (presented on top in Figure 1 ) and factors that may be obstacles (at the bottom in Figure 1 ).
| Decision of what, where, and how to study
Health system leaders prioritized studies that generate value to health care delivery systems in the short term, did not incur direct costs, and had low opportunity costs. Some decision makers acknowledged the potential return on investment of their directly funding some embedded trials, but were disinclined to self-fund studies that would benefit other systems at no cost, ie, a free-riding problem. Informants noted that external funders often required a level of methodological rigor and end points that are not routinely collected, making it more difficult for the systems to incorporate the studies into routine practice.
Many of the interviewed researchers noted a tension between
quickly collecting enough information to address the most urgent questions that the delivery system has and conducting studies that provide stronger, more generalizable, evidence. Most administrators and clinical leaders indicated that they usually could not wait for federal grant review and award mechanisms or commit to studies that required long implementation times.
All the interviewed researchers understood the ethical requirements for equipoise and exposure of research subjects to minimal risk.
However, most identified the research governance process as an obstacle, because of the length of time it added and inconsistency in determining whether a pragmatic study could be classified as minimal risk and whether the requirement for written informed consent could be waived. One of them noted that cluster randomization was sometimes chosen because it lessened the need for individual informed consent.
| Implementation of PCT
In the interviews, some researchers mentioned that if the research disturbs health care delivery too much, this can create obstacles. This can happen if the intervention is burdensome to implement, if clinicians must spend time to recruit patients, obtain informed consent, or record data for the study. Those and other factors may cause slow or insufficient recruitment into the study. A few researchers also discussed issues related to study operations such as practical and technical issues around data collection and that unexpected changes in leadership at study sites (where the new leader has not "bought into" the study) or changes in the usual care control arm may create obstacles.
| Dissemination and implementation of results
While all informants noted the importance of disseminating trial results and implementation when appropriate, a couple of interviewees mentioned examples where successful interventions were not imple- 
| Conclusion and recommendations
The published experience with embedded PCTs indicates that they can be a relatively inexpensive and effective way to address important knowledge gaps. The PCTs' high external validity makes them well suited to assess comparative effectiveness and cost-effectiveness.
They can also evaluate differences in cost and quality of life that would not be realistic for conventional clinical trials to address. Although at present, they complement rather than replace regulatory trials for pharmaceuticals, some pragmatic aspects may be incorporated into such trials in light of the growing interest in real-world evidence, and the FDA's commitment to developing standards for using it. 16 Until then, PCTs have their main role when there is insufficient knowledge on comparative effectiveness and effectiveness in the real world clinical setting with heterogeneous populations. 17 Our interviews highlighted 3 major considerations that must be addressed for embedded PCTs to become more widely used:
1.
The decision of what to study and how. Embedded PCTs should be attuned to the needs of health care delivery systems through more direct links between clinical decision makers, investigators, and research sponsors.
One possibility for extending pragmatic embedded research to a larger group of organizations is to create methods for multiple organizations to fund and/or participate in a single, coordinated PCT. Consortium approaches might work particularly well for cluster randomization, but multicenter studies incur substantial added time, effort, and cost to address governance, implementation, and analysis needs.
There are also ways researchers can make embedded research more relevant for health care when designing and evaluating trials. 4 A practical way to increase value for end users is for researchers to engage directly and substantively with patients, clinicians, and health system leaders to establish research priorities. Another is to collect resource consumption and/or cost data to guide decisions about implementation.
Research funders for their part should recognize that PCTs are only well suited for some of the questions for which they currently fund conventional RCTs and strive to identify areas of overlap between their needs and priorities and those of delivery systems.
2. Implementation of PCTs. Embedded research must not unduly disturb health care delivery. An important aspect of pragmatic trials is to use data that are available and keep end points few to restrict data collection to a minimum. Nonetheless, it is important to implement the intervention in a manner that assures that the treatment arms will differ sufficiently to assess the impact of the intervention and collect enough data to understand both the effect of the intervention and how well it has been implemented.
3. Disseminate and implement findings. Academic publishers would do well to adopt guidelines specifically for reporting embedded PCTs.
They should ensure that the review process evaluates them on their own merits and does not treating pragmatic research as if it were exploratory. Furthermore, the research community may need to develop alternative dissemination venues.
Generally, the pragmatic nature of these trials should facilitate implementation of results in clinical practice. However, as for all clinical practices, for successful implementation, creation of implementation toolkits that contain detailed standard operating procedures, instructional guides for local implementers, and 
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